Cargando…

The central GLP-1: implications for food and drug reward

Glucagon-like-peptide-1 (GLP-1) and its long acting analogs comprise a novel class of type 2 diabetes (T2D) treatment. What makes them unique among other T2D drugs is their concurrent ability to reduce food intake, a great benefit considering the frequent comorbidity of T2D and obesity. The precise...

Descripción completa

Detalles Bibliográficos
Autor principal:	Skibicka, Karolina P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2013
Materias:	Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3796262/ https://www.ncbi.nlm.nih.gov/pubmed/24133407 http://dx.doi.org/10.3389/fnins.2013.00181

Ejemplares similares

Gut Peptide GLP-1 and Its Analogue, Exendin-4, Decrease Alcohol Intake and Reward
por: Shirazi, Rozita H., et al.
Publicado: (2013)

Activation of the GLP-1 Receptors in the Nucleus of the Solitary Tract Reduces Food Reward Behavior and Targets the Mesolimbic System
por: Richard, Jennifer E., et al.
Publicado: (2015)

Central Oxytocin and Food Intake: Focus on Macronutrient-Driven Reward
por: Klockars, Anica, et al.
Publicado: (2015)

Self-assembled GLP-1/glucagon peptide nanofibrils prolong inhibition of food intake
por: Ouberai, Myriam M., et al.
Publicado: (2023)

Role of ghrelin in food reward: impact of ghrelin on sucrose self-administration and mesolimbic dopamine and acetylcholine receptor gene expression
por: Skibicka, Karolina P, et al.
Publicado: (2012)

Sex-divergent effects of hindbrain GLP-1-producing neuron activation in rats
por: Lopez-Ferreras, Lorena, et al.
Publicado: (2023)

Ghrelin increases intake of rewarding food in rodents
por: Egecioglu, Emil, et al.
Publicado: (2010)

Future Perspectives on GLP-1 Receptor Agonists and GLP-1/glucagon Receptor Co-agonists in the Treatment of NAFLD
por: Seghieri, Marta, et al.
Publicado: (2018)

[Gly²]-GLP-2, But Not Glucagon or [D-Ala²]-GLP-1, Controls Collagen Crosslinking in Murine Osteoblast Cultures
por: Mieczkowska, Aleksandra, et al.
Publicado: (2021)

Emerging Role of Caveolin-1 in GLP-1 Action
por: Puddu, Alessandra, et al.
Publicado: (2021)

GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects
por: Zhao, Xin, et al.
Publicado: (2021)

The Role of GLP-1 Signaling in Hypoglycemia due to Hyperinsulinism
por: Danowitz, Melinda, et al.
Publicado: (2022)

Sex and estrogens alter the action of glucagon-like peptide-1 on reward
por: Richard, Jennifer E., et al.
Publicado: (2016)

Obesity and Dietary Added Sugar Interact to Affect Postprandial GLP-1 and Its Relationship to Striatal Responses to Food Cues and Feeding Behavior
por: Jones, Sabrina, et al.
Publicado: (2021)

Circadian secretion rhythm of GLP-1 and its influencing factors
por: Liu, Chuanfeng, et al.
Publicado: (2022)

GLP-1RAs caused gastrointestinal adverse reactions of drug withdrawal: a system review and network meta-analysis
por: Zhang, Ziqi, et al.
Publicado: (2023)

GLP-1 based therapeutics: simultaneously combating T2DM and obesity
por: Heppner, Kristy M., et al.
Publicado: (2015)

Pleiotropic Effects of GLP-1 and Analogs on Cell Signaling, Metabolism, and Function
por: Rowlands, Jordan, et al.
Publicado: (2018)

From the Incretin Concept and the Discovery of GLP-1 to Today's Diabetes Therapy
por: Holst, Jens Juul
Publicado: (2019)

GLP-1 and Underlying Beneficial Actions in Alzheimer’s Disease, Hypertension, and NASH
por: Li, Qiu-Xuan, et al.
Publicado: (2021)

The mechanism and efficacy of GLP-1 receptor agonists in the treatment of Alzheimer’s disease
por: Du, Haiyang, et al.
Publicado: (2022)

Corrigendum: GLP-1RAs caused gastrointestinal adverse reactions of drug withdrawal: a system review and network meta-analysis
por: Zhang, Ziqi, et al.
Publicado: (2023)

Gastrointestinal Distension by Pectin-Containing Carbonated Solution Suppresses Food Intake and Enhances Glucose Tolerance via GLP-1 Secretion and Vagal Afferent Activation
por: Ohbayashi, Kento, et al.
Publicado: (2021)

GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach
por: Wang, Jing-Yue, et al.
Publicado: (2023)

Lateral hypothalamic GLP-1 receptors are critical for the control of food reinforcement, ingestive behavior and body weight
por: López-Ferreras, L, et al.
Publicado: (2018)

Brain GLP‐1 and the regulation of food intake: GLP‐1 action in the brain and its implications for GLP‐1 receptor agonists in obesity treatment
por: Trapp, Stefan, et al.
Publicado: (2021)

Free Versus Fixed-Ratio Combination of Basal Insulin and GLP-1 Receptor Agonists in Type 2 Diabetes Uncontrolled With GLP-1 Receptor Agonists: A Systematic Review and Indirect Treatment Comparison
por: Jung, Han Na, et al.
Publicado: (2022)

Basal insulin intensification with GLP-1RA and dual GIP and GLP-1RA in patients with uncontrolled type 2 diabetes mellitus: A rapid review of randomized controlled trials and meta-analysis
por: Lisco, Giuseppe, et al.
Publicado: (2022)

Insights Into GLP-1 and GIP Actions Emerging From Vildagliptin Mechanism Studies in Man
por: Foley, James E.
Publicado: (2019)

Striking the Balance: GLP-1/Glucagon Co-Agonism as a Treatment Strategy for Obesity
por: Hope, David C. D., et al.
Publicado: (2021)

Benefits of Sustained Upregulated Unimolecular GLP-1 and CCK Receptor Signalling in Obesity-Diabetes
por: Tanday, Neil, et al.
Publicado: (2021)

From an Empty Stomach to Anxiolysis: Molecular and Behavioral Assessment of Sex Differences in the Ghrelin Axis of Rats
por: Börchers, Stina, et al.
Publicado: (2022)

Effects of SGLT2 Inhibitors and GLP-1 Receptor Agonists on Renin-Angiotensin-Aldosterone System
por: Puglisi, Soraya, et al.
Publicado: (2021)

Glucagon Like Peptide 1 and MicroRNA in Metabolic Diseases: Focusing on GLP1 Action on miRNAs
por: Capuani, Barbara, et al.
Publicado: (2018)

Repurposed Analog of GLP-1 Ameliorates Hyperglycemia in Type 1 Diabetic Mice Through Pancreatic Cell Reprogramming
por: Villalba, Adrian, et al.
Publicado: (2020)

A specific gut microbiota signature is associated with an enhanced GLP-1 and GLP-2 secretion and improved metabolic control in patients with type 2 diabetes after metabolic Roux-en-Y gastric bypass
por: Hernández-Montoliu, Laura, et al.
Publicado: (2023)

GLP-1 Analogs and DPP-4 Inhibitors in Type 2 Diabetes Therapy: Review of Head-to-Head Clinical Trials
por: Gilbert, Matthew P., et al.
Publicado: (2020)

Hunger and Satiety Gauge Reward Sensitivity
por: Cassidy, Ryan Michael, et al.
Publicado: (2017)

GLP-1 modulates the supramammillary nucleus-lateral hypothalamic neurocircuit to control ingestive and motivated behavior in a sex divergent manner
por: López-Ferreras, Lorena, et al.
Publicado: (2018)

Endogenous GLP-1 mediates postprandial reductions in activation in central reward and satiety areas in patients with type 2 diabetes
por: ten Kulve, Jennifer S., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_2tprndgscek7ea220dfvnhkh9i